MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers

BACKGROUND: The majority of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations respond well to osimertinib (AZD9291), a third generation mutation-selective epidermal growth factor receptor (EGFR) inhibitor. The current study focuses on determining whether targeting MEK/E...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Gu, Jiajia, Yao, Weilong, Shi, Puyi, Zhang, Guojing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7381372/
https://ncbi.nlm.nih.gov/pubmed/32497272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32996
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares